Bruker (BRKR) Cash & Equivalents (2010 - 2026)

Bruker (BRKR) has reported Cash & Equivalents for 17 consecutive years, with $184.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 100.98% year-over-year to $184.9 million; the trailing twelve-month figure through Jun 2026 stood at $184.9 million (up 100.98% YoY), and the FY2025 full-year result was $298.8 million, up 62.92% from the prior year.
• Cash & Equivalents grew to $184.9 million in Q2 2026 per BRKR's latest filing, from $133.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $816.1 million in Q1 2022 and bottomed at $92.0 million in Q2 2025.
• Historically, Cash & Equivalents has averaged $381.3 million across 5 years, with a median of $319.4 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents slumped 70.48% in 2024, then jumped 100.98% in 2026.
• Over 5 years, Cash & Equivalents stood at $645.5 million in 2022, then slipped by 24.35% to $488.3 million in 2023, then tumbled by 62.44% to $183.4 million in 2024, then soared by 62.92% to $298.8 million in 2025, then plunged by 38.12% to $184.9 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $184.9 million, $133.4 million, and $298.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.